An interventional study of U=U testing messaging scripts and U=U adherence messaging scripts in HIV Infections, Men and Treatment Adherence, sponsored by Desmond Tutu HIV Foundation. Recruiting at 2 sites in South Africa. Open to male participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by Desmond Tutu HIV Foundation · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 305 studies in HIV Infections with a site in South Africa — 15 open to participants now, 36 under way, 15 of them phase 3. HIV Infections · South Africa.
Among the 305 studies in HIV Infections with a site in South Africa, this one is the 16th largest by planned enrollment of the 267 interventional ones that give a count, is one of 10 that started in 2023, is one of 49 with no phase, reaches primary completion later than 20 of the 35 other live ones, and was the 278th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 305 studies in HIV Infections with a site in South Africa are open now. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa, Romania, Uganda
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Emory University · Sites in South Africa
Ages 18+ · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in South Africa
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in South Africa
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 15 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
305 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 92 · Phase 3 85 · Phase 4 21
First in 1999; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,642 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 280 across the 267 interventional studies, 513 across the 35 observational. Of the 248 that completed or were terminated, 128 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 305 have an industry lead sponsor. The 10 most frequent:
Desmond Tutu HIV Foundation is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Desmond Tutu HIV Foundation has 3 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
9 of the studies in HIV Infections with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06694753International AIDS Vaccine InitiativeSafety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. | 2026-12-08 |
| NCT05602376Desmond Tutu HIV FoundationImproving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging | 2026-12-31 |
| NCT05553236University of California, San FranciscoPragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis | 2027-01 |
| NCT05933226University of Maryland, College ParkProject Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa | 2027-02 |
| NCT05633056Columbia UniversityAn Adaptive Randomized Controlled Trial | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 305 studies in HIV Infections with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the impact of U=U messaging and counseling on gaps in the HIV care cascade for men, including testing uptake and ART initiation (Aim 1), achieving viral suppression and retention in care (Aim 2) in two provinces in South Africa. The U=U message communicates the compelling idea that PLHIV who take ART and have an undetectable viral load (\<200 copies/mL) cannot sexually transmit HIV. Additionally, the investigators will conduct a multi-method evaluation to inform future implementation of U=U messaging interventions (Aim 3).
Increasing the coverage of HIV testing and treatment among people living with HIV (PLHIV) is essential for ending the global AIDS epidemic. Unfortunately, compared to women, men living with HIV (MLHIV) are less likely to know their HIV status, start anti retroviral treatment, or achieve viral suppression. Given that new HIV infections among women are driven, in part, by men's testing and treatment gaps, reducing the gender gap in testing uptake, treatment initiation and achievement of viral suppression by men must be prioritized in order to accelerate the decline in HIV incidence among women, improve men's HIV-related health outcomes and achieve the UNAIDS 95-95-95 goals by 2030.
In this study, the investigators evaluate the effectiveness of Undetectable Equals Untransmittable or "U=U" messaging for closing the gender gap in the HIV cascade. Particularly for men, the U=U message has the potential to accelerate progress towards the 95-95-95 targets by: 1) reducing anxiety associated with HIV testing (1st 95); 2) encouraging people who test HIV positive to initiate ART (2nd 95); and 3) reducing fear of transmitting HIV to sexual partners by promoting treatment adherence to achieve viral suppression (3rd 95). While there is a growing knowledge of Treatment as Prevention (TasP)/U=U among PLWH in Western countries, the reach and penetration of the U=U message in sub-Saharan Africa has been limited and few studies have tested the impacted of accessible U=U messages on ART uptake and adherence in sub-Saharan Africa.
Building on the investigators prior work on U=U messaging informed by behavioral economics and human-centered design, they propose to conduct two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2). The investigators will also conduct a multi-method evaluation to inform future implementation of U=U messaging interventions. To improve the generalizability of the findings, the study will be conducted in two provinces in South Africa (Western and Eastern Cape). If effective, the intervention can shape global HIV testing and treatment counselling guidelines and practices. The expert, multi-institutional collaborations will allow for the application of previous research findings, leverage unique implementation platforms and resources, and rapidly disseminate the findings.
Inclusion Criteria:
AIM 1:
AIM 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aim 1: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve HIV testing uptake by men
Behavioral: U=U testing messaging scripts
Aim 2: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve ART adherence, HIV viral suppression and retention in care
Behavioral: U=U adherence messaging scripts
Aim 1: SoC messaging scripts will be used to both invite men for CB-HTS and to refer those that test HIV-positive for DoH clinic-based ART initiation Aim 2: SoC messaging as part of ART initiation counselling, and as part of their HIV care and treatment program
On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
ART initiation among those invited to test for HIV
Proportions of ART initiation among all people invited to test in each study arm over the year of Aim 1 data collection
Time frame: 30-day follow-up period
Proportion with viral load suppression
Proportions of people who have documented viral suppression at the 6-month visit in each study arm during Aim 2
Time frame: 6-month visit
% who agree to testing
Proportions of testing uptake among all people invited to test in each study arm over the year of Aim 1 enrolment.
Time frame: Baseline
Proportion retained in care
Proportions of people who have a recorded viral load at their 12-month visit in each study arm during Aim 2.
Time frame: 12-month visit
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Informed consent form, Analytic code
Access criteria: Based on contractual agreement
Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 45 months is above that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Desmond Tutu HIV Foundation